» Articles » PMID: 27037360

Proteomic Analysis Reveals a Novel Mutator S (MutS) Partner Involved in Mismatch Repair Pathway

Overview
Date 2016 Apr 3
PMID 27037360
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The mismatch repair (MMR) family is a highly conserved group of proteins that function in correcting base-base and insertion-deletion mismatches generated during DNA replication. Disruption of this process results in characteristic microsatellite instability (MSI), repair defects, and susceptibility to cancer. However, a significant fraction of MSI-positive cancers express MMR genes at normal levels and do not carry detectable mutation in known MMR genes, suggesting that additional factors and/or mechanisms may exist to explain these MSI phenotypes in patients. To systematically investigate the MMR pathway, we conducted a proteomic analysis and identified MMR-associated protein complexes using tandem-affinity purification coupled with mass spectrometry (TAP-MS) method. The mass spectrometry data have been deposited to the ProteomeXchange with identifier PXD003014 and DOI 10.6019/PXD003014. We identified 230 high-confidence candidate interaction proteins (HCIPs). We subsequently focused on MSH2, an essential component of the MMR pathway and uncovered a novel MSH2-binding partner, WDHD1. We further demonstrated that WDHD1 forms a stable complex with MSH2 and MSH3 or MSH6,i.e.the MutS complexes. The specific MSH2/WDHD1 interaction is mediated by the second lever domain of MSH2 and Ala(1123)site of WDHD1. Moreover, we showed that, just like MSH2-deficient cells, depletion of WDHD1 also led to 6-thioguanine (6-TG) resistance, indicating that WDHD1 likely contributes to the MMR pathway. Taken together, our study uncovers new components involved in the MMR pathway, which provides candidate genes that may be responsible for the development of MSI-positive cancers.

Citing Articles

Proteomic analysis of ferroptosis pathways reveals a role of CEPT1 in suppressing ferroptosis.

Liu X, Chen Z, Yan Y, Zandkarimi F, Nie L, Li Q Protein Cell. 2024; 15(9):686-703.

PMID: 38430542 PMC: 11365556. DOI: 10.1093/procel/pwae004.


Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy.

Cui Z, Zou F, Wang R, Wang L, Cheng F, Wang L World J Surg Oncol. 2023; 21(1):309.

PMID: 37759234 PMC: 10523704. DOI: 10.1186/s12957-023-03187-3.


WD Repeat and HMG Box DNA Binding Protein 1: An Oncoprotein at the Hub of Tumorigenesis and a Novel Therapeutic Target.

Zhang Z, Zhu Q Int J Mol Sci. 2023; 24(15).

PMID: 37569867 PMC: 10420296. DOI: 10.3390/ijms241512494.


WDHD1 is over-expressed in nasopharyngeal carcinoma and may control the expression of ITGAV.

Wu J, Niu Y, Huang S, Tan Y, Yang Z, Fang Y FEBS Open Bio. 2022; 13(1):102-117.

PMID: 36345604 PMC: 9811654. DOI: 10.1002/2211-5463.13519.


Rad5 and Its Human Homologs, HLTF and SHPRH, Are Novel Interactors of Mismatch Repair.

Miller A, Mao G, Knicely B, Daniels H, Rahal C, Putnam C Front Cell Dev Biol. 2022; 10:843121.

PMID: 35784486 PMC: 9243396. DOI: 10.3389/fcell.2022.843121.


References
1.
Chun J, Buechelmaier E, Powell S . Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway. Mol Cell Biol. 2012; 33(2):387-95. PMC: 3554112. DOI: 10.1128/MCB.00465-12. View

2.
Mellacheruvu D, Wright Z, Couzens A, Lambert J, St-Denis N, Li T . The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods. 2013; 10(8):730-6. PMC: 3773500. DOI: 10.1038/nmeth.2557. View

3.
Tran P, Simon J, Liskay R . Interactions of Exo1p with components of MutLalpha in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. 2001; 98(17):9760-5. PMC: 55526. DOI: 10.1073/pnas.161175998. View

4.
Nguyen L, Barsky D, Fernandes M, Wilson 3rd D . Molecular interactions of human Exo1 with DNA. Nucleic Acids Res. 2002; 30(4):942-9. PMC: 100345. DOI: 10.1093/nar/30.4.942. View

5.
Gu L, Zhang F, Qiu L, Li G . Mismatch repair deficiency in hematological malignancies with microsatellite instability. Oncogene. 2002; 21(37):5758-64. DOI: 10.1038/sj.onc.1205695. View